John Smither

John Smither

DirectoratArcutis Biotherapeutics· In proxies 2023–2025

Pay in FY2024+103% from the year before · Arcutis Biotherapeutics stock +331.3% the same year

John Smither was paid $2.1M in FY2024 (Dec), up 103%. Arcutis Biotherapeutics stock rose 331.3% that year.

Pay$100 in the stock at the end of FY22 → $94
Pay is from the Summary Compensation Table of each Arcutis Biotherapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. GENELUXPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. Arcutis BiotherapeuticsPublic company · 3 yr
    • Chief Financial Officer2023 – Present · 3 yrStock in role +124%
  3. NewAmsterdam PharmaPublic company · 4 yr
    • Director2022 – Present · 4 yrNo stock prices for these years
  4. Applied Molecular Transport Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. eFFECTOR Therapeutics Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • GENELUXDirector · 2 yr on the boardIndependentAudit—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?